Rounding out a very successful year, Accreditation for Cardiovascular Excellence (ACE) reports they have reached record-breaking numbers of accreditation applications for cardiac cath labs in 2013. “Accreditation applications have more than doubled since 2012,” said Mary Heisler, RN, BA, ACE Executive Director. “More labs are realizing the importance of accountable metrics and know it’s time to get started on the quality journey with ACE.”

The American Heart Association’s Council on Clinical Cardiology presented its James B. Herrick Award for outstanding achievement in clinical cardiology to Marc Alan Pfeffer, M.D., Ph.D., of Harvard Medical School “for acclaimed research showing how cardiac muscle damage occurs during a heart attack, a discovery that led to new life-saving treatment.”

Neovasc Inc. (TSXV: NVC) today reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the symptoms and functioning of patients disabled by previously untreatable refractory angina. The COSIRA trial also confirmed that the Reducer is safe and well-tolerated, with no reports of device-related serious adverse events. The safety and efficacy data from the randomized, controlled COSIRA trial is consistent with results seen in previous non-randomized pilot studies of the Reducer.

Memorial is pleased to announce the formation of a unique partnership with one of the area’s most well known centers for cardiovascular care – The Heart Institute of East Texas.

BIOTRONIK announced today that the PK Papyrus covered coronary stent system has received CE mark for the treatment of acute coronary artery perforation.

OrbusNeich today announced that new clinical data presented at TCT 2013 show durable outcomes as well as excellent early healing and optimal neointimal suppression out to 24 months following placement of the COMBO Dual Therapy Stent. These results from the EGO-COMBO Study were presented by Stephen W.L. Lee, M.D., of the Queen Mary Hospital, University of Hong Kong, China, at the annual interventional cardiology conference in San Francisco.

Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) were presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference held in San Francisco, October 27 – November 1, 2013. The MiStent SES is a thin-strut drug-eluting stent distinguished by a rapidly absorbable coating designed to control drug release, and which was developed to optimize vessel healing in patients with coronary artery disease.

Corindus Vascular Robotics<http://www.corindus.com/>, the leader in precision vascular robotics, will showcase its FDA-approved CorPath System at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2013 annual meeting, Oct. 27 - Nov. 1 in San Francisco, CA. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Experts from renowned hospitals and healthcare organizations across the country will deliver onsite presentations and answer questions about their clinical experience with robotic-assisted angioplasty and the significant advantages in stent precision and clinical outcomes utilizing the CorPath System.